Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group […]
STAT+: Pharmalittle: We’re reading about a Roche obesity drug, a clash over 340B claims data, and more
Hello, everyone, and how are you today? We are just fine, thank you, despite the frigid temperature and cold winds wafting across the Pharmalot campus, where our official mascots are, thankfully, snoozing away in a nearby corner. As for us, we are going about our usual business — foraging for interesting and saucy items, and […]
Women On Menopause Hormone Therapy Lose More Weight With Zepbound, Study Finds
TUESDAY, Jan. 27, 2026 — Good news for women taking hormone therapy for menopause: You might find that weight-loss drugs are more effective.Women on hormone therapy lost 35% more weight while taking Zepbound (tirzepatide), researchers recently r…
STAT+: Roche moves obesity drug to pivotal trials after mid-stage success
Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after reporting Tuesday that the drug led to significant weight loss in a mid-stage trial. The drug, known as CT-388, led to a placebo-adjusted weight loss of 18.3% after 48 weeks in the Phase 2 trial at the highest dose tested […]
Large quantity of Mounjaro stolen from company
The weight loss drug is taken by thieves from Phoenix Healthcare Distribution in St Albans.
One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.
Why exercise is essential for restoring fitness after GLP-1-based weight loss
This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.
The future GLP-1 might be a gene therapy: Report
As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24. GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, mimic a naturally occurring gut hormone to suppress appetite, promote a feeling of fullness, stimulate […]
Menopause Hormone Therapy May Boost GLP-1 Drug Benefits
(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated. Among 120 women with overweight or obesity…